Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$66.73
0.831.26%
À la fermeture: -
$67.71
0.981.47%
Après les heures de négociation: 7:55 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
CVS Health Corp a un objectif de cours consensuel de 567,61 $ basé sur les notes de 38 analystes. Le plus haut est de 1 350 $ émis par HSBC le 10 mai 2024<. Le plus bas est de 100 $ émis par Deutsche Bank le 5 août 2024. Les 3 dernières notations d'analystes ont été publiées par New Street Research, Goldman Sachs et Deutsche Bank respectivement le 6 août 2024, le 5 août 2024 et le 5 août 2024. Avec un objectif de cours moyen de 118,33 $ entre New Street Research, Goldman Sachs et Deutsche Bank, il existe une hausse implicite de 0,21 % pour CVS Health Corp à partir de ces notations d'analystes les plus récentes.
Sociétés d'analyse émettant des recommandations1
Baird
Morgan Stanley
Barclays
UBS
Jefferies
1calculé à partir des notes des analystes
Notes d'analystes pour CVS Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/14/2025 | — | Baird | $71 → $82 | Upgrade | Neutral → Outperform | |||
08/01/2025 | — | Morgan Stanley | $80 → $82 | Maintains | Overweight | |||
08/01/2025 | — | Barclays | $79 → $80 | Maintains | Overweight | |||
07/22/2025 | — | UBS | $71 → $67 | Maintains | Neutral | |||
06/30/2025 | — | Jefferies | $74 → $80 | Maintains | Buy | |||
06/02/2025 | — | Barclays | $82 → $79 | Maintains | Overweight | |||
05/12/2025 | — | Truist Securities | $82 → $84 | Maintains | Buy | |||
05/06/2025 | — | Wells Fargo | $76 → $84 | Maintains | Overweight | |||
05/05/2025 | — | RBC Capital | $74 → $81 | Maintains | Outperform | |||
05/02/2025 | — | UBS | $67 → $71 | Maintains | Neutral | |||
05/02/2025 | — | Barclays | $73 → $82 | Maintains | Overweight | |||
04/15/2025 | — | Baird | $51 → $71 | Maintains | Neutral | |||
04/11/2025 | — | Truist Securities | $76 → $82 | Maintains | Buy | |||
04/09/2025 | — | Mizuho | $70 → $76 | Maintains | Outperform | |||
03/21/2025 | — | Piper Sandler | $72 → $74 | Maintains | Overweight | |||
02/18/2025 | — | JP Morgan | $80 → $81 | Maintains | Overweight | |||
02/13/2025 | — | Wells Fargo | $68 → $73 | Maintains | Overweight | |||
02/13/2025 | — | Truist Securities | $60 → $76 | Maintains | Buy | |||
02/13/2025 | — | Barclays | $71 → $73 | Maintains | Overweight | |||
02/13/2025 | — | Leerink Partners | $55 → $75 | Upgrade | Market Perform → Outperform | |||
01/27/2025 | — | Evercore ISI Group | $60 → $65 | Maintains | Outperform | |||
01/06/2025 | — | Truist Securities | $67 → $60 | Maintains | Buy | |||
12/03/2024 | — | Deutsche Bank | $66 → $66 | Upgrade | Hold → Buy | |||
11/25/2024 | — | TD Cowen | $73 → $80 | Maintains | Buy | |||
11/25/2024 | — | Piper Sandler | $72 → $64 | Maintains | Overweight | |||
11/20/2024 | — | Truist Securities | $76 → $67 | Reiterates | Buy → Buy | |||
11/18/2024 | — | Wells Fargo | $60 → $66 | Upgrade | Equal-Weight → Overweight | |||
11/15/2024 | — | RBC Capital | $68 → $58 | Maintains | Outperform | |||
11/07/2024 | — | UBS | $60 → $62 | Maintains | Neutral | |||
11/07/2024 | — | Barclays | $75 → $71 | Maintains | Overweight | |||
11/04/2024 | — | Wells Fargo | $61 → $60 | Maintains | Equal-Weight | |||
10/24/2024 | — | Mizuho | $73 → $66 | Maintains | Outperform | |||
10/23/2024 | — | Barclays | $82 → $75 | Maintains | Overweight | |||
10/11/2024 | — | Truist Securities | $66 → $76 | Maintains | Buy | |||
10/10/2024 | — | Barclays | $63 → $82 | Upgrade | Equal-Weight → Overweight | |||
10/08/2024 | — | Evercore ISI Group | $62 → $75 | Maintains | Outperform | |||
10/04/2024 | — | TD Cowen | $59 → $85 | Upgrade | Hold → Buy | |||
10/01/2024 | — | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/16/2024 | — | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/10/2024 | — | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/04/2024 | — | RBC Capital | $68 → $68 | Reiterates | Outperform → Outperform | |||
08/19/2024 | — | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
08/12/2024 | — | Wells Fargo | $60 → $61 | Maintains | Equal-Weight | |||
08/09/2024 | — | Deutsche Bank | $64 → $63 | Maintains | Hold | |||
08/08/2024 | — | Barclays | $65 → $63 | Maintains | Equal-Weight | |||
08/08/2024 | — | Cantor Fitzgerald | $58 → $62 | Maintains | Neutral | |||
08/08/2024 | — | Evercore ISI Group | $65 → $62 | Maintains | Outperform | |||
07/23/2024 | — | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
06/12/2024 | — | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
05/30/2024 | — | JP Morgan | $101 → $86 | Maintains | Overweight | |||
05/30/2024 | — | Baird | → $61 | Initiates | → Neutral | |||
05/08/2024 | — | Argus Research | $100 → $80 | Maintains | Buy | |||
05/07/2024 | — | Wells Fargo | $76 → $60 | Maintains | Equal-Weight | |||
05/07/2024 | — | TD Cowen | $99 → $59 | Downgrade | Buy → Hold | |||
05/02/2024 | — | B of A Securities | $95 → $77 | Maintains | Buy | |||
05/02/2024 | — | Goldman Sachs | $85 → $74 | Maintains | Buy | |||
05/02/2024 | — | Barclays | $78 → $63 | Maintains | Equal-Weight | |||
05/02/2024 | — | UBS | $85 → $60 | Downgrade | Buy → Neutral | |||
05/02/2024 | — | Truist Securities | $90 → $66 | Reiterates | Buy → Buy | |||
05/02/2024 | — | Mizuho | $86 → $72 | Maintains | Buy | |||
05/01/2024 | — | Leerink Partners | → $60 | Downgrade | Outperform → Market Perform | |||
05/01/2024 | — | Cantor Fitzgerald | $87 → $58 | Downgrade | Overweight → Neutral | |||
04/10/2024 | — | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
04/08/2024 | — | Wells Fargo | $83 → $76 | Maintains | Equal-Weight | |||
04/04/2024 | — | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
03/15/2024 | — | Piper Sandler | $93 → $94 | Maintains | Overweight | |||
03/06/2024 | — | Barclays | → $78 | Initiates | → Equal-Weight | |||
02/26/2024 | — | Leerink Partners | → $88 | Initiates | → Outperform | |||
02/08/2024 | — | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
02/08/2024 | — | RBC Capital | $86 → $84 | Maintains | Outperform | |||
12/22/2023 | — | HSBC | → $94 | Initiates | → Buy | |||
12/11/2023 | — | TD Cowen | $102 → $99 | Maintains | Outperform | |||
11/21/2023 | — | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
11/02/2023 | — | Mizuho | $88 → $86 | Maintains | Buy | |||
11/02/2023 | — | RBC Capital | $91 → $86 | Maintains | Outperform | |||
11/02/2023 | — | Morgan Stanley | $110 → $100 | Maintains | Overweight | |||
09/19/2023 | — | Evercore ISI Group | $81 → $83 | Upgrade | In-Line → Outperform | |||
09/14/2023 | — | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
09/12/2023 | — | Wolfe Research | → $80 | Upgrade | Peer Perform → Outperform | |||
09/01/2023 | — | Piper Sandler | $85 → $82 | Maintains | Overweight | |||
08/18/2023 | — | RBC Capital | → $91 | Reiterates | Outperform → Outperform | |||
08/18/2023 | — | Edward Jones | — | Downgrade | Buy → Hold | |||
08/04/2023 | — | Raymond James | $90 → $85 | Maintains | Outperform | |||
08/03/2023 | — | Truist Securities | $103 → $98 | Maintains | Buy | |||
08/03/2023 | — | Morgan Stanley | $120 → $110 | Maintains | Overweight | |||
08/03/2023 | — | RBC Capital | $102 → $91 | Maintains | Outperform | |||
08/03/2023 | — | Barclays | $89 → $86 | Maintains | Overweight | |||
07/12/2023 | — | Barclays | $90 → $89 | Maintains | Overweight | |||
07/11/2023 | — | Mizuho | $120 → $88 | Maintains | Buy | |||
07/07/2023 | — | JP Morgan | $114 → $106 | Maintains | Overweight | |||
06/20/2023 | — | Truist Securities | $109 → $103 | Maintains | Buy | |||
05/30/2023 | — | JP Morgan | $125 → $114 | Maintains | Overweight | |||
05/26/2023 | — | Piper Sandler | → $85 | Initiates | → Overweight | |||
05/09/2023 | — | RBC Capital | → $102 | Reiterates | → Outperform | |||
05/08/2023 | — | Wells Fargo | $95 → $76 | Maintains | Equal-Weight | |||
05/08/2023 | — | Credit Suisse | $125 → $96 | Maintains | Outperform | |||
05/08/2023 | — | Raymond James | $110 → $90 | Maintains | Outperform | |||
05/05/2023 | — | Goldman Sachs | $100 → $88 | Maintains | Buy | |||
05/04/2023 | — | Goldman Sachs | $100 → $88 | Maintains | Buy | |||
05/04/2023 | — | Barclays | $100 → $90 | Maintains | Overweight |
FAQ
Quel est le cours indicatif de l'action CVS Health (CVS) ?
Le dernier objectif de prix pour CVS Health (NYSE:CVS) a été rapporté par Baird le août 14, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $82.00 s'attendant à ce que CVS se rise dans les 12 prochains mois (un possible changement de 21.10% upside). 42 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour CVS Health (CVS) ?
La dernière note d'analyste pour CVS Health (NYSE:CVS) a été fournie par Baird, et CVS Health amélioré leur note outperform.
Quand a eu lieu la dernière mise à niveau pour CVS Health (CVS) ?
La dernière amélioration pour CVS Health Corp a eu lieu le août 14, 2025 lorsque Baird a augmenté leur objectif de prix à $82. Baird avait précédemment a neutral pour CVS Health Corp.
Quand a eu lieu la dernière dégradation pour CVS Health (CVS) ?
La dernière réduction pour CVS Health Corp a eu lieu le mai 7, 2024 lorsque TD Cowen a changé leur objectif de prix de $99 à $59 pour CVS Health Corp.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour CVS Health (CVS) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de CVS Health, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour CVS Health a été déposée le août 14, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 14, 2026.
La note d'analyste pour CVS Health (CVS) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de CVS Health (CVS) était un amélioré avec un objectif de prix de $71.00 à $82.00. Le prix actuel de CVS Health (CVS) est de $67.71, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.